Literature DB >> 10780509

AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats.

E D Levin1, C Bettegowda, J Blosser, J Gordon.   

Abstract

Nicotinic acetylcholine systems have been found to be important for learning and memory function. The prototypic nicotinic agonist nicotine has been shown in a variety of studies to improve aspects of cognitive function. The specific involvement of nicotinic receptor subtypes is now being investigated. The involvement of alpha7 nicotinic receptors was assessed in this project using a novel alpha7 nicotinic agonist, AR-R 17779. Repeated doses (subcutaneous injection 20 min before testing) of the racemic mixture AR-R 13489 and its active isomer AR-R 17779 were assessed in adult female Sprague-Dawley rats using the eight-arm radial maze. AR-R 13489 (2 mg/kg) caused a significant improvement of long-term win-shift acquisition after 3 weeks of training (n = 10 per group). The same dose of AR-R 17779 also caused a significant improvement in repeated acquisition within each daily session in the radial-arm maze. In another study, the active isomer AR-R 17779 significantly improved radial-arm maze working memory function in rats with lesions to the septohippocampal projection. Fimbria-fornix lesions significantly impaired working memory performance and AR-R 17779 significantly reversed that impairment. These studies showed that alpha7 nicotinic agonist treatment improved learning in two radial-arm maze tasks and reversed working memory impairment caused by fimbria-fornix sections, providing evidence for alpha7 involvement in learning and memory, and the potential therapeutic use of AR-R 17779.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10780509     DOI: 10.1097/00008877-199911000-00014

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  51 in total

1.  beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons.

Authors:  Q Liu ; H Kawai; D K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 4.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 5.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

6.  An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification.

Authors:  M V Guseva; D M Hopkins; J R Pauly
Journal:  Pharmacol Biochem Behav       Date:  2006-06-06       Impact factor: 3.533

Review 7.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

8.  Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors.

Authors:  Alexander I Chernyavsky; Juan Arredondo; Maryna Skok; Sergei A Grando
Journal:  Int Immunopharmacol       Date:  2009-12-18       Impact factor: 4.932

9.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

10.  Rat neuronal nicotinic acetylcholine receptors containing alpha7 subunit: pharmacological properties of ligand binding and function.

Authors:  Yingxian Xiao; Galya R Abdrakhmanova; Maryna Baydyuk; Susan Hernandez; Kenneth J Kellar
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.